http://www.gsk.com/media/ GlaxoSmithKline is a leading healthcare company that helps people to do more, feel better and live longer. This RSS feed contains press releases and investor news. http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10098.htm GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International (NYSE: VRX) today announced that they have entered into an exclusive worldwide collaboration agreement for the investigational drug retigabine, a first in class neuronal potassium channel opener for treatment of adult epilepsy patients with refractory partial onset seizures. Thu, 28 Aug 2008 12:00:00 GMT http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10098.htm http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10091.htm Phase III pivotal study of ofatumumab in refractory CLL meets primary endpoint Thu, 31 Jul 2008 15:30:00 GMT http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10091.htm http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10089.htm Industry and academia link up in pioneering agreement Thu, 24 Jul 2008 14:00:00 GMT http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10089.htm http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10088.htm In a presentation to investors today, Andrew Witty, CEO GlaxoSmithKline, set out three new strategic priorities that aim to increase growth, reduce risk and improve GSK’s long-term financial performance. Wed, 23 Jul 2008 11:00:00 GMT http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10088.htm http://www.gsk.com/investors/quarterly_results.htm Results announced for the second quarter 2008 on Wednesday 23 July Wed, 23 Jul 2008 11:00:00 GMT http://www.gsk.com/investors/quarterly_results.htm http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10086.htm GlaxoSmithKline (GSK) today announced a transformational agreement to significantly extend its pharmaceutical portfolio in emerging markets. Wed, 23 Jul 2008 08:00:00 GMT http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10086.htm http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10085.htm Dan Troy has been appointed as Senior Vice President and General Counsel for GlaxoSmithKline (GSK), and will join the company on 2nd September 2008. Tue, 22 Jul 2008 17:00:00 GMT http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10085.htm http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10084.htm University of Cambridge to pioneer drug development by “academic incubators”. Mon, 21 Jul 2008 09:00:00 GMT http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10084.htm http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10083.htm GlaxoSmithKline plc (GSK) today announced that it has reached a settlement in the litigation with Biota Holdings Limited regarding the commercialisation of Relenza (zanamivir). Mon, 21 Jul 2008 07:00:00 GMT http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10083.htm